Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity

• Status: Active, not recruiting
• Trial end date: 2021-02-01
• Target enrollment: 0
• Participant gender: All

Summary

this work aims to investigate the effect of intrathecal administration of Morphine, Dexmedetomidine or both in combination on cellular immunity and cytokine production in patients undergoing major abdominal cancer surgeries.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Bupivacaine; Dexmedetomidine; Morphine

Criteria

Inclusion Criteria:

• ASA I-II patients scheduled for major abdominal cancer surgeries

Exclusion Criteria:

• patients with known allergy to the study drugs,

• significant cardiac, respiratory, renal or hepatic disease,

• drug or alcohol abuse,

• psychiatric illness that would interfere with perception and assessment of pain.